Barclays
BDSX icon

Barclays’s Biodesix BDSX Stock Holding History

Barclays’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$8 – 5253
2025
Q3 		$8 Sell
1
-8
-89% -$62 ﹤0.01% 5403
2025
Q2 		$51 Sell
9
-2,763
-100% -$22.3K ﹤0.01% 5118
2025
Q1 		$34.7K Sell
2,772
-2,841
-51% -$54.5K ﹤0.01% 4687
2024
Q4 		$172K Buy
5,613
+4,461
+387% +$131K ﹤0.01% 4377
2024
Q3 		$41K Buy
1,152
+1,059
+1,139% +$36.4K ﹤0.01% 4790
2024
Q2 		$2.84K Sell
93
-372
-80% -$10.6K ﹤0.01% 4616
2024
Q1 		$13.3K Hold
465
– – ﹤0.01% 4788
2023
Q4 		$17.1K Buy
+465
New +$14.6K ﹤0.01% 4925
2023
Q3 		– Sell
-12
Closed -$304 – 4600
2023
Q2 		$304 Buy
+12
New +$360 ﹤0.01% 4405
2022
Q2 		– Sell
-114
Closed -$4K – 5021
2022
Q1 		$4K Buy
+114
New +$7.45K ﹤0.01% 4716

Other funds holding BDSX

TAM
Telemark Asset Management Boston, Massachusetts $1.38B AUM 71.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Barclays's BDSX Position: Q4 2025 in Review

Barclays sold out of Biodesix (BDSX) in Q4 2025, closing a stake of 1 share — an estimated $8 sold.

Barclays first reported a position in BDSX in Q1 2022 and held it in 10 quarters. The position peaked at $172K in Q4 2024. 26 funds tracked by Wall St. Rank hold BDSX as of Q4 2025.

  • Barclays reported no remaining Biodesix position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 1 Biodesix share in Q4 2025, an estimated $8.
  • Barclays first reported a position in Biodesix in Q1 2022 and held it in 10 quarters.
  • Barclays's Biodesix position peaked at $172K in Q4 2024.
  • 26 funds tracked by Wall St. Rank held Biodesix as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.